Literature DB >> 7621238

High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.

W W Zhang1, X Fang, W Mazur, B A French, R N Georges, J A Roth.   

Abstract

A replication-defective and helper-independent recombinant p53 adenovirus was generated. The virus, Ad5CMV-p53, carries an expression cassette that contains human cytomegalovirus E1 promoter, human wild-type p53 cDNA, and SV40 early polyadenylation signal. Four human non-small-cell lung cancer cell lines representing differences in p53 configuration were used to evaluate the Ad5CMV-p53 virus. In the H358 cell line, which has a homozygous deletion of p53, the p53 gene was transferred with 97% to 100% efficiency, as detected by immunohistochemical analysis, when the cells were infected with Ad5CMV-p53 at a multiplicity of infection of 30 to 50 plaque-forming units/cell. Western blots showed that the p53 protein was expressed at a high level. The protein expression peaked at day 3 after infection and lasted for at least 15 days. Growth of the Ad5CMV-p53 virus-infected H358 cells was inhibited 79%, whereas that of noninfected cells or the cells infected with the control virus was not inhibited. Growth of cell line H322, which has a point mutation in p53, was inhibited 72% by Ad5CMV-p53, while that of cell line H460 containing wild-type p53 was less affected (28% inhibition). Tests in nude mice demonstrated that tumorigenicity of the Ad5CMV-p53-treated H358 cells was greatly inhibited. In a mouse model of orthotopic human lung cancer, the tumorigenic H226Br cells, with a point mutation in p53, were inoculated intratracheally 3 days before the virus treatment. Intratracheal instillation of Ad5CMV-p53 prevented tumor formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7621238

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  29 in total

Review 1.  Gene therapy in lung cancer.

Authors:  S G Swisher; J A Roth
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  p53 Gene therapy for lung cancer.

Authors:  Stephen G Swisher; Jack A Roth
Journal:  Curr Oncol Rep       Date:  2002-07       Impact factor: 5.075

3.  Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines.

Authors:  Sang Young Ryu; Kidong Kim; Woo Sik Lee; Hee Chung Kwon; Kee Ho Lee; Chang Min Kim; Soon-Beom Kang
Journal:  J Gynecol Oncol       Date:  2009-03-31       Impact factor: 4.401

Review 4.  Gene therapy for carcinoma of the breast.

Authors:  M A Stoff-Khalili; P Dall; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-06       Impact factor: 5.987

Review 5.  Gene therapy for respiratory diseases: potential applications and difficulties.

Authors:  E W Alton; D M Geddes
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

6.  Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene.

Authors:  Yutaka Maeda; Wendy W Hwang-Verslues; Gang Wei; Takuya Fukazawa; Mary L Durbin; Laurie B Owen; Xuan Liu; Frances M Sladek
Journal:  Biochem J       Date:  2006-12-01       Impact factor: 3.857

Review 7.  Gene Therapy for Lung Cancer.

Authors:  Humberto Lara-Guerra; Jack A Roth
Journal:  Crit Rev Oncog       Date:  2016

8.  MicroRNA-221/222 regulate ox-LDL-induced endothelial apoptosis via Ets-1/p21 inhibition.

Authors:  Bing Qin; Yuze Cao; Huan Yang; Bo Xiao; Zhengqi Lu
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

9.  In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.

Authors:  Jeong-Heum Baek; Munna L Agarwal; Raymond R Tubbs; Alex Vladisavljevic; Hiroshi Tomita; Ronald M Bukowski; Jeffrey W Milsom; Jin-Man Kim; Jin-Young Kwak
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

10.  p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo.

Authors:  Marijeta Kralj; Jasminka Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.